journal article·2024

Inherently targeted estradiol-derived carbon dots for selective killing of ER (+) breast cancer cells via oridonin-triggered p53 pathway activation

Aftab Hossain Khan, Ambalika Basak, Afreen Zaman, Prasanta Kumar Das

Journal of Materials Chemistry B· Volume 12· Issue 45
Publisher page

Abstract

-estradiol and citric acid following a solvothermal method. The synthesized carbon dots were characterized using spectroscopic and microscopic techniques. The water soluble, intrinsically fluorescent E2-CA-CD showed excellent biocompatibility in MCF-7, MDA-MB-231 as well as NIH3T3 cells and demonstrated target specific bioimaging in ER (+) MCF-7 cells due to the overexpressed ER receptors. Furthermore, oridonin, a well-known hydrophobic anticancer drug capable of upregulating the p53 pathway, was loaded on the carbon dots to increase its bioavailability. E2-CA-CD-Ori caused ∼2.2 times higher killing in ER (+) MCF-7 cells compared to ER (-) MDA-MB-231 cells and normal cells NIH3T3. Also, E2-CA-CD-Ori showed ∼3 fold better killing in MCF-7 cells compared to native oridonin. E2-CA-CD-Ori-induced killing of MCF-7 cells took place through the early to late apoptotic pathway along with the elevation of the intracellular ROS level. Importantly, E2-CA-CD-Ori triggered the activation of the p53 pathway in MCF-7 cells, which in turn induced apoptosis involving the upregulation of Bax and downregulation of Bcl-2 leading to the selective and efficient killing of ER (+) MCF-7 cells.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Carbon and Quantum Dots Applications · Graphene and Nanomaterials Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biological Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata – 700 032, India

Funding

Science and Engineering Research Board

References (55)

Show source-provided references
1. Wilkinson · Br. J. Radiol. · 2022 · 95 · 2021103310.1259/bjr.20211033 ↗
2. Althuis · Cancer Epidemiol., Biomarkers Prev. · 2004 · 13 · 155810.1158/1055-9965.1558.13.10 ↗
3. Allred · Mod. Pathol. · 2010 · 23 · S5210.1038/modpathol.2010.55 ↗
4. Tryfonidis · Cancer Treat. Rev. · 2016 · 50 · 6810.1016/j.ctrv.2016.08.008 ↗
5. Ma · Oncology · 2009 · 23 · 133
6. Xiong · J. Pharm. Sci. · 2005 · 94 · 178210.1002/jps.20397 ↗
7. Mondal · J. Controlled Release · 2013 · 172 · 83210.1016/j.jconrel.2013.08.302 ↗
8. Nasongkla · Nano Lett. · 2006 · 6 · 242710.1021/nl061412u ↗
9. Du · Angew. Chem., Int. Ed. · 2010 · 49 · 362110.1002/anie.200907210 ↗
10. Brahmachari · J. Mater. Chem. B · 2014 · 2 · 116010.1039/c3tb21334j ↗
11. Yang · J. Phys. Chem. C · 2008 · 112 · 1755410.1021/jp806751k ↗
12. Kim · J. Am. Chem. Soc. · 2009 · 131 · 136010.1021/ja808137c ↗
13. Ghosh · Adv. Drug Delivery Rev. · 2008 · 60 · 130710.1016/j.addr.2008.03.016 ↗
14. Huang · J. Mater. Chem. B · 2015 · 3 · 65110.1039/C4TB01650E ↗
15. Lee · Chem. Soc. Rev. · 2012 · 41 · 265610.1039/C2CS15261D ↗
16. Cutler · Chem. Rev. · 2013 · 113 · 85810.1021/cr3003104 ↗
17. Luo · Expert Opin. Drug Delivery · 2012 · 9 · 4710.1517/17425247.2012.638624 ↗
18. Zhang · Acc. Chem. Res. · 2011 · 44 · 85310.1021/ar2000277 ↗
19. Li · Chem. Soc. Rev. · 2012 · 41 · 259010.1039/c1cs15246g ↗
20. Derfus · Nano Lett. · 2004 · 4 · 1110.1021/nl0347334 ↗
21. Cheng · Nanomedicine · 2011 · 6 · 132710.2217/nnm.11.56 ↗
22. Chakraborty · ACS Sustainable Chem. Eng. · 2018 · 6 · 466110.1021/acssuschemeng.7b03691 ↗
23. Chowdhury · Chem. – Eur. J. · 2023 · 29 · e20230092810.1002/chem.202300928 ↗
24. Paudyal · ACS Appl. Bio Mater. · 2022 · 5 · 330010.1021/acsabm.2c00309 ↗
25. Du · Small · 2019 · 15 · e180508710.1002/smll.201805087 ↗
26. Maiti · Chem. Commun. · 2013 · 49 · 885110.1039/c3cc44492a ↗
27. Das · ACS Appl. Mater. Interfaces · 2016 · 8 · 2569110.1021/acsami.6b06353 ↗
28. Chowdhury · ACS Appl. Bio Mater. · 2021 · 4 · 513210.1021/acsabm.1c00348 ↗
29. Bartkowski · Chem. – Eur. J. · 2024 · 30 · e20230398210.1002/chem.202303982 ↗
30. Feng · ACS Appl. Mater. Interfaces · 2016 · 8 · 1873210.1021/acsami.6b06695 ↗
31. Baker · Angew. Chem., Int. Ed. · 2010 · 49 · 672610.1002/anie.200906623 ↗
32. Zhu · Angew. Chem., Int. Ed. · 2013 · 52 · 395310.1002/anie.201300519 ↗
33. Bourlinos · Small · 2008 · 4 · 45510.1002/smll.200700578 ↗
34. Ding · ACS Appl. Mater. Interfaces · 2015 · 7 · 688910.1021/acsami.5b00628 ↗
35. Ghosh · Colloids Surf., B · 2016 · 142 · 36710.1016/j.colsurfb.2016.03.005 ↗
36. Ciocca · Trends Endocrinol. Metab. · 1997 · 8 · 31310.1016/S1043-2760(97)00122-7 ↗
37. Moulder · Cancers · 2018 · 10 · 18910.3390/cancers10060189 ↗
38. Marvalim · Theranostics · 2023 · 13 · 142110.7150/thno.81847 ↗
39. Cui · Acta Pharmacol. Sin. · 2007 · 28 · 105710.1111/j.1745-7254.2007.00588.x ↗
40. Zhao · Front. Bioeng. Biotechnol. · 2021 · 9 · 60057910.3389/fbioe.2021.600579 ↗
41. Paoletti · Carbohydr. Polym. · 2022 · 314 · 12090010.1016/j.carbpol.2023.120900 ↗
42. Mamnoon · Mol. Pharmaceutics · 2020 · 17 · 431210.1021/acs.molpharmaceut.0c00754 ↗
43. Sarkar · ACS Sustainable Chem. Eng. · 2017 · 5 · 835610.1021/acssuschemeng.7b02130 ↗
44. Pandit · ACS Appl. Bio Mater. · 2019 · 2 · 339310.1021/acsabm.9b00374 ↗
45. Zhi · Nanoscale · 2019 · 11 · 2041110.1039/C9NR05028K ↗
46. Han · J. Mater. Chem. C · 2022 · 10 · 1182710.1039/D2TC02044K ↗
47. Mondal · Mater. Lett.: X · 2023 · 18 · 100195
48. Gan · Nanoscale · 2016 · 8 · 779410.1039/C6NR00605A ↗
49. Hobza · Chem. Rev. · 2000 · 100 · 425310.1021/cr990050q ↗
50. Li · Front. Pharmacol. · 2021 · 12 · 64582410.3389/fphar.2021.645824 ↗
51. Hassin · Nat. Rev. Drug Discovery · 2023 · 22 · 12710.1038/s41573-022-00571-8 ↗
52. Ciciarello · J. Biol. Chem. · 2001 · 276 · 1920510.1074/jbc.M009528200 ↗
53. Bunz · Science · 1998 · 282 · 149710.1126/science.282.5393.1497 ↗
54. Fritsche · Oncogene · 1993 · 8 · 307
55. Ungerleider · Breast Cancer Res. · 2018 · 20 · 11510.1186/s13058-018-1044-5 ↗